In this webinar, VentureCrowd CEO Steve Maarbani talks to the CEO and Executive Chair of ESN Cleer about the technology, its competitive advantages, and their plans for commercialisation and exit.
Short on time? Here's the summary:
Sadly, many of us will know someone close to us who has died suddenly and unexpectedly from a heart attack.
The unfortunate statistics are:
- Heart failure is one of the largest causes of death globally
- 1 in 5 people will suffer heart failure during their lifetime
- Most cases of heart failure are not detected until symptoms appear and by then it is often too late to properly treat the problem
ESN Cleer may have the solution to that problem, having developed a patented saliva-based diagnostic that detects the early risk of heart failure with 95% accuracy. The test is designed to be simple to use, affordable and can deliver results within minutes to a matter of days.
The product does not require TGA approval in Australia but is currently going through NATA accreditation – National Association of Testing Australia – this year and then plans to obtain accreditation in the US early next year.
The funds being raised will be used to achieve those milestones, which will then position the business to either lock in distribution arrangements or license the technology to a larger pharmaceutical or medical devices organisation to distribute through their own channels.